Clinical trials: Ovarian Hyperstimulation Syndrome
Polycystic Ovary Syndrome
Myo-Inositol for Ovarian Stimulation and ICSI Outcomes in Women With PCOS
Polycystic ovary syndrome (PCOS) is a common endocrine disorder that may affect ovarian function, insulin sensitivity, and fertility.
- Trial name
- NCT07779850
- Testing
- Myo-Inositol, Folic Acid
- Where
- Egypt
- Volunteers
- 88 people
- Sponsor
- Kafrelsheikh University
Infertility, Sterility
Real-world Evidence on Follitropin Delta Individual Dosing
As part of the in vitro fertilisation treatment, ovarian stimulation is routinely performed. For this purpose, FSH preparations are used.
- Trial name
- NCT05173597
- Testing
- Follitropin delta
- Where
- Germany
- Volunteers
- 850 people
- Sponsor
- University of Luebeck
Controlled Ovarian Hyperstimulation, Polycystic Ovarian Syndrome
Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women With Polycystic Ovarian Syndrome
The purpose of this study is to compare the use of the progesterone-primed ovarian stimulation protocol versus GnRH antagonist protocol in women with polycystic ovarian syndrome (PCOS) regarding the number of oocytes retrieved…
- Trial name
- NCT06812559
- Testing
- Progesterone, GnRH antagonist (Cetrorelix)
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- El Shatby University Hospital for Obstetrics and Gynecology
Ovarian Hyperstimulation Syndrome
Comparative Study Between Calcium Gluconate With Diosmin, Cabergoline and Cabergoline With Diosmin
Ovarian hyperstimulation syndrome is a potentially fatal iatrogenic condition. This syndrome is characterized by a sudden increase of the vascular permeability which results in the development of a massive extravascular exudate…
- Trial name
- NCT06333691
- Testing
- Calcium Gluconate
- Where
- Egypt
- Volunteers
- 180 people
- Sponsor
- Minia University
Ovarian Hyperstimulation Syndrome
The Letrozole Administration During Luteal Phase
To investigate the effect of letrozole in patients who have high risk of ovarian hyperstimulation syndrome (OHSS) after oocyte retrieval, the incidence of OHSS were calculated between letrozole group and supporting treatment…
- Trial name
- NCT02686151
- Testing
- Letrozole, Polygeline, Sodium Chloride
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The Affiliated Hospital of Inner Mongolia Medical University
Ovarian Hyperstimulation Syndrome, Pregnancy Related
Freeze All Strategy Versus Fresh Embryo Transfer After GnRH Analogue Trigger
Ovarian hyperstimulation syndrome (OHSS) is one of the most dangerous complications of assisted reproduction technology (ART), described in approximatively 3 to 10% of stimulation cycles although an underestimation of the real…
- Trial name
- NCT05362734
- Testing
- obstetric outcomes after fresh versus cryopreserved embryo transfer
- Volunteers
- 1,396 people
- Sponsor
- Istituto Clinico Humanitas
Ovarian Hyperstimulation Syndrome, Infertility, Female
Dual Trigger" in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome
The present study aims to evaluate whether the use of a "dual trigger" can improve IVF outcomes, compared to GnRH agonist (GnRH-a) alone, in patients at high risk of OHSS undergoing a freeze-all cycle.
- Trial name
- NCT05638529
- Testing
- Pregnyl (1,500) IU, 1.5 mL of normal saline
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- Mount Sinai Hospital, Canada
Ovarian Hyperstimulation Syndrome, Frozen-thawed Embryo Transfers
Association Between Live Birth Rate and Serum Progesterone During Hormonal Replacement Therapy
Nowadays, frozen-thawed embryo transfers (FET) are expending. This practice avoids risk of ovarian hyperstimulation syndrome (OHSS), as well as allowing better synchronization between endometrium and embryo, which is fundamental…
- Trial name
- PROGEVOL (NCT05588635)
- Testing
- Identification of predictive factors
- Where
- France
- Volunteers
- 168 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
Ovarian Hyperstimulation Syndrome
Montelukast for Prevention & Treatment of OHSS
montelukast \& dydrgesteron will be given to cases with suspected or proven ovarian hyperstimulation in one group in comparison with dydrogesteron alone in the other group.
- Trial name
- NCT03794037
- Testing
- dydrgesterone 10 mg( tab)/12hs/14 days, montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Benha University
Ovarian Hyperstimulation Syndrome
Ovarian Hyperstimulation Syndrome Using Calcium Infusion
the incidence of OHSS and clinical outcomes after calcium IV infusion in high-risk women undergoing ART
- Trial name
- NCT05198128
- Testing
- Calcium intravenous infsuion, 0.9 % saline
- Volunteers
- 200 people
- Sponsor
- Al-Azhar University
Polycystic Ovary Syndrome, Ovarian Hyperstimulation Syndrome
The Four Methods of Ovarian Stimulation in Patients With Polycystic Ovarian Syndrome
This study is a randomized controlled clinical trial to compare the pregnancy outcomes of mild and minimal stimulation in infertile women with polycystic ovarian syndrome.
- Trial name
- NCT03876145
- Testing
- Minimal ovarian stimulation
- Where
- Iran
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Royan Institute
Pregnancy Early, Miscarriage
Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High Responders
Gonadotropin Releasing Hormone agonist (GnRHa) triggering is used as an alternative to human chorionic gonadotropin (hCG) in GnRH antagonist protocol to eliminate the risk of ovarian hyperstimulation syndrome (OHSS).
- Conditions
- Pregnancy Early, Miscarriage, Ovarian Hyperstimulation Syndrome
- Trial name
- NCT04797338
- Testing
- Synarel, 0.2 Mg/Inh Nasal Spray, Estrofem, Utrogestan
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Assaf-Harofeh Medical Center
Ovarian Hyperstimulation Syndrome
Luteal Phase Supplementation With Recombinant LH After GnRh Agonist Oocytes Triggering in Women at Risk of OHSS
The purpose of this study is to prove that luteal phase supplementation with recombinant LH can solve the luteal phase deficiency after Gnrh agonist oocytes triggering in women at risk of OHSS
- Trial name
- NCT02200952
- Testing
- recombinant LH
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- San Carlo Public Hospital, Potenza, Italy
Ovarian Hyperstimulation Syndrome, Cardiovascular Diseases
Medical Assistance for the Procreation and Risk of Thrombosis.
This study aims at evaluating clincal practice regarding prevention of arterial and venous thrombosis following ovarian stimulation.
- Conditions
- Ovarian Hyperstimulation Syndrome, Cardiovascular Diseases, Embolism and Thrombosis
- Trial name
- AMPERT (NCT02610608)
- Testing
- ovarian stimulation
- Where
- 9 sites in France
- Volunteers
- 129 people
- Sponsor
- University Hospital, Brest
Ovarian Hyperstimulation Syndrome
Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response
lines of evidence that support nature of ovarian hyperstimulation syndrome (OHSS) as "defective mineralocorticoid response" are cited, our hypothesis is tested clinically in both prophylaxis against and treatment of OHSS.
- Trial name
- NCT04351126
- Testing
- Fludrocortisone 0.1 Milligrams (mg), Bromocriptine
- Where
- Egypt
- Volunteers
- 107 people
- Sponsor
- Ganin Fertility Center
No Condition
Comparison of Clinical Outcomes Between IVM and Minimal Stimulation IVF in Patients With PCOS
Polycystic ovarian syndrome (PCOS) is most common endocrinologic disease in women of reproductive age with incidence of 6.6 ~ 8%.
- Trial name
- NCT03134482
- Testing
- IVM, Minimal stimulation IVF
- Where
- 2 sites in South Korea
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- CHA University
Ovarian Hyperstimulation Syndrome
Coasting Versus Antagonist Protocol in Patients at High Risk of OHSS
The aim of this work is to study the value of GnRH antagonist subcutaneous administration as an alternative to coasting in prevention of severe OHSS and its impact on embryos quality \& the outcome of ICSI.
- Trial name
- NCT03996434
- Testing
- Gonadotropin, Antagonist
- Where
- 2 sites in Egypt
- Volunteers
- 300 people
- Sponsor
- ClinAmygate
Ovarian Hyperstimulation Syndrome, Hypercoagulability
Ovarian Hyperstimulation Syndrome in Patients Triggered by GnRH Agonist for Excessive Follicular Response
In the literature, the risk of moderate to severe OHSS is 3 to 6% and reaches 31% in high risk populations 9 days after oocyte triggering with hCG.
- Trial name
- COAGO (NCT02701452)
- Testing
- COAGO
- Volunteers
- 1 people
- Sponsor
- University Hospital, Lille
Endometrial Receptivity, Ovarian Hyperstimulation Syndrome
Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation
The purpose of this study is to compare gene expression profiles in endometrial biopsies during the window of implantation after triggers of oocyte maturation using GnRH agonist or hCG and compared with their natural cycles in…
- Trial name
- NCT01606709
- Testing
- GnRH agonist, hCG
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- UConn Health
Ovarian Hyperstimulation Syndrome
Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS
This a prospective randomized double blind study involving patients at high risk of OHSS development with peak serum E2 levels < 4,000 pg/ml comparing the ongoing pregnancy rates in patients who receive adjuvant hCG 1,000 IU at…
- Trial name
- NCT01815138
- Testing
- hCG
- Where
- United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- UConn Health